Skip to main content

Liver cirrhosis and its complications

Call for Content

Liver cirrhosis is a consequence of chronic liver diseases with a high morbidity and mortality. It is the 11th most common cause of death worldwide. Liver cirrhosis related complications, such as ascites, variceal bleeding, hepatic encephalopathy, jaundice, and hepatocellular carcinoma herald the progression of liver diseases. 

New Content ItemIn recent years, the management of liver cirrhosis and its complications has greatly evolved. However, prognosis is still dismal, and liver transplantation remains the sole curative treatment option.

This Special Collection aims to collate original research articles and review articles regarding the management of liver cirrhosis and its complications. We are also interested in high-quality systematic reviews and meta-analyses in this field.

Potential topics include but are not limited to the following:

  • Management of compensated liver cirrhosis
  • Current and future therapies for cirrhosis associated portal hypertension
  • Management of upper gastrointestinal bleeding, ascites, hepatic encephalopathy, hepatic hydrothorax, hypersplenism, hepatic myelopathy, cirrhotic cardiomyopathy, infection, acute kidney injury, malnutrition, and portal vein thrombosis in liver cirrhosis
  • Use of liver support devices and extracorporeal therapies in advanced cirrhosis
  • Use of direct antiviral drugs, statins, anticoagulants, non-selective beta-blockers, human albumin infusions, and endoscopic variceal treatment in liver cirrhosis
  • Early use of transjugular intrahepatic portosystemic shunt (TIPS) in severe complications of liver cirrhosis
  • Early assessment of renal function, cardiac function, and nutritional status in liver cirrhosis
  • Role of gut microbiota in cirrhosis and associated clinical events
  • Pathogenesis, prognosis, and management of acute-on-chronic liver failure (ACLF)
  • Risk factors and surveillance for hepatocellular carcinoma in liver cirrhosis
  • Primary and secondary prophylaxis of gastroesophageal variceal bleeding
  • Impact of spontaneous portosystemic shunts (SPSS) on patients’ outcomes and its management in liver cirrhosis
  • Management of liver transplantation candidates and recipients
  • Short- and long-term prognosis of liver cirrhosis

The collection launches on May 15th, 2022 and will remain open for submissions until 31st March 2023.

Please email Dr Marie-Therese Noedl, the inhouse editor for BMC Gastroenterology (marie-therese.noedl@springernature.com) if you would like more information before you submit. 

Submission Guidelines

This collection welcomes submissions of Research articles, including systematic reviews, on the topic of liver cirrhosis and its complications as well as management thereof. Reviews, Guidelines and Study Protocols will be considered at the discretion of the journal’s Editor. Please note that unsolicited Reviews and Guidelines will not be considered as per our submission guidelines. 

Articles will undergo the journal’s standard peer-review process overseen by our Guest Editors, Dr Xingshun Qi, Dr Cyriac Abby Philips, Dr Fernando Gomes Romeiro and Dr Le Wang. Articles will be added to the Collection as they are published.

Before submitting your manuscript, please ensure you have carefully read the submission guidelines for BMC Gastroenterology. Please ensure you highlight in your cover letter that you are submitting to a collection. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Liver cirrhosis and its complications". 

Meet the Guest Editors

Dr Xingshun Qi

New Content ItemDr Xingshun Qi is a deputy director at the Department of Gastroenterology at General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area) now. His major research interests are the management of liver cirrhosis, portal hypertension (especially portal vein thrombosis and Budd-Chiari syndrome), and hepatocellular carcinoma. His H-index is 40 with 5359 citations to date.

Dr Cyriac Abby Philips

New Content Item

Dr Philips is a clinician scientist at The Liver Institute, Rajagiri Hospital, Kerala, India. His pioneering work in Hepatology was the introduction of healthy donor fecal transplant for patients with severe alcohol-associated hepatitis, the first randomized trial on colloids versus crystalloids in sepsis-induced hypotension in cirrhotics and novel data on clinical outcomes and toxicology of complementary and alternative medicine related liver injury from India, known as Ayush-liver injury.

Dr Fernando Gomes Romeiro

New Content ItemAfter graduating in Medicine, Dr. Fernando Romeiro concluded the Internal Medicine and Gastroenterology medical residencies at São Paulo State University (Universidade Estadual Paulista Júlio de Mesquita Filho), where he also concluded his Doctorate in Internal Medicine Pathophysiology. He received the title of Gastroenterology specialist from the Brazilian Federation of Gastroenterology and is a member of the Brazilian Society of Hepatology. He is professor of Clinical Gastroenterology in the same University, where he is also the supervisor of the Gastroenterology Medical Residency. He is a board member of two Postgraduate courses and takes part of the CPFig Research Group - Clinical Research Group on Liver Pathobiology, in the Directory of CNPq Brazil Research Groups.

Dr Le Wang

New Content ItemDr Le Wang is affiliated to the College of General Hospital of Northern Theater Command of China Medical University now. Her major research interests are the management of liver cirrhosis and portal hypertension (especially portal vein thrombosis and gastroesophageal variceal bleeding).

  1. Alcohol cessation is the cornerstone of treatment for alcohol-related cirrhosis. This study evaluated associations between medical conversations about alcohol use disorder (AUD) treatment, AUD treatment engage...

    Authors: Wheytnie Alexandre, Haseeb Muhammad, Olufunso Agbalajobi, Grace Zhang, Theresa Gmelin, Adeyinka Adejumo, Alan Noll, Naudia L. Jonassaint, Andrea DiMartini, Ramon Bataller and Shari S. Rogal
    Citation: BMC Gastroenterology 2023 23:29
  2. Regorafenib is an oral multikinase inhibitor and became the first second-line systemic treatment for hepatocellular carcinoma (HCC) following the phase III RESORCE trial. This single-center study retrospective...

    Authors: Qingwei Zhu, Wei Rao, Junyu Huo, Zixiang Li, Song Wang, Wensheng Qiu, Ge Guan, Yang Xin, Ning Fan, Jinzhen Cai and Liqun Wu
    Citation: BMC Gastroenterology 2023 23:28
  3. In China, hepatorenal syndrome is a serious complication in the decompensated stage of hepatitis B cirrhosis, which requires early clinical intervention, so the early diagnosis of hepatorenal syndrome is cruci...

    Authors: Shouhao Wang, Zhewen Zhou, Chengan Xu, Hanzhu Chen, Wenya Ren, Xingdi Yang, Qiaoqiao Yin, Wei Zheng and Hongying Pan
    Citation: BMC Gastroenterology 2023 23:1
  4. There is strong evidence demonstrating the incidence of Acute Coronary Syndrome (ACS) among patients with cirrhosis, with the initiation of antiplatelet therapy being subject to debate due to an increased risk...

    Authors: Shameel Shafqat, Ajeet Kumar Lohana, Rajesh Kumar Bansari and Om Parkash
    Citation: BMC Gastroenterology 2022 22:543
  5. Early prediction of severe acute pancreatitis (SAP) plays an important role in timely treatment decisions. Soluble T cell immunoglobulin and mucin domain-3 (sTIM-3) has been applied as a potential biomarker fo...

    Authors: Fushuang Wang, Minghui Zhu, Yao Meng and Min Lin
    Citation: BMC Gastroenterology 2022 22:522
  6. The aim of this study was to investigate the efficacy and safety of the combination of low-molecular-weight heparin + dexamethasone after partial splenic embolization in cirrhotic patients with massive splenom...

    Authors: Haohao Lu, Chuansheng Zheng, Bin Xiong and Xiangwen Xia
    Citation: BMC Gastroenterology 2022 22:470

    The Correction to this article has been published in BMC Gastroenterology 2023 23:27

  7. Patients with low HBV DNA levels (< 2000 IU/mL), HBV DNA negative, and HBsAg-negative hepatitis B virus(HBV)infection can still progress to decompensated cirrhosis; however, clinical research data in such pati...

    Authors: Xu Huang, Meimei Yan, Zerun Deng, Lei Yao, Dan Han and Lihua Sun
    Citation: BMC Gastroenterology 2022 22:452
  8. Aberrant cytokeratin 7 expression by hepatocytes (CK7+Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC). This study attempted ...

    Authors: Hong-Li Liu, An-Yin Yang, Qing-Fang Xiong, Yan-Dan Zhong, Du-Xian Liu, Ping Huang, Xiao-Ning Feng, Yu Zhang and Yong-Feng Yang
    Citation: BMC Gastroenterology 2022 22:443
  9. Portal hypertensive gastropathy (PHG) is often underestimated in clinical diagnosis. Gastrointestinal bleeding in cirrhosis of PHG accounts for approximately 10% of upper gastrointestinal bleeding. However, th...

    Authors: Ran Wu, Kunyi Liu, Chengyi Shi, Hui Tian and Na Wang
    Citation: BMC Gastroenterology 2022 22:436
  10. We retrospectively compared the effect of endoscopic variceal obturation (EVO) and retrograde transvenous obliteration (RTO) in acute cardiofundal variceal bleeding.

    Authors: Han Ah Lee, Jungwon Kwak, Sung Bum Cho, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Seung Up Kim, Hyonggin An, Hyung Joon Yim, Jong Eun Yeon and Yeon Seok Seo
    Citation: BMC Gastroenterology 2022 22:355